PRKAA1 and non-small cell lung carcinoma: In ASP4132, treated where ASP4132 is an AMPK activator in the NSCLC cells, AMPK downstream actions such as mTORC1 inhibition, PDGFR and EGFR degradation, Akt suppression, and autophagy activation were identified.